A modern, humane healthcare system should honor a person’s values not only in how they live with serious illness, but in how they die. Medical aid in dying (MAID)—the option for a terminally ill, mentally capable adult to request and self-administer medication to end life peacefully—does precisely that. It isn’t a substitute for hospice or…
Are DTC ads effective? It depends on who you ask. Some DTC marketers will throw out vanity metrics like awareness, but as far as driving business objectives, new Rx’s, there is no doubt that pharmaceutical DTC ads are less effective. However, they do drive education on certain conditions. The path between awareness and actually filling…
Morgan Stanley Research recently revised its projections for the global obesity drug market, estimating a potential peak of $150 billion by 2035—a sharp increase from its earlier forecast of $105 billion. The optimism stems from unprecedented sales growth: in 2024, obesity drugs already generated $15 billion in revenue, cementing their status as the hottest therapeutic category in…
On Thursday, Eli Lilly responded to the Trump administration’s plan to lower U.S. drug costs with a stunningly tone-deaf statement: the company threatened to raise prices in Europe to “align” them with what patients pay in other developed countries. This isn’t leadership—it’s corporate hostage-taking. Instead of addressing the fundamental issue of drug affordability in the…
The FDA’s recent approvals of new Alzheimer’s drugs have been met with headlines filled with hope. Families, desperate for a lifeline, cling to the idea that these treatments could slow — or even stop — a disease that robs people of memory, independence, and identity. But as much as we want a medical breakthrough, the…